Compounds having activity as inhibitors of apoptosis

Details Compounds having activity as inhibitors of apoptosis Compounds having activity as inhibitors of apoptosis

2005-11-10

2009-10-13

Dentz, Bernard (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C544S133000, C546S199000, C514S233200, C514S322000, C514S366000

Reexamination Certificate

active

07601846

ABSTRACT:
The present invention provides compounds that can protect mammalian cells from the damaging effects of chemotherapy, irradiation, or in other situations in which it is desirable to protect tissue from the consequences of clinical or environmental stress.

REFERENCES:
patent: 3843681 (1974-10-01), Demerson et al.
patent: 4020062 (1977-04-01), Hardtmann
patent: 4337760 (1982-07-01), Rubin
patent: 4497817 (1985-02-01), Murase et al.
patent: 4537889 (1985-08-01), Spitzer
patent: 4559157 (1985-12-01), Smith et al.
patent: 4567263 (1986-01-01), Eicken et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4762705 (1988-08-01), Rubin
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5561151 (1996-10-01), Young et al.
patent: 5696260 (1997-12-01), Shaw et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 6066741 (2000-05-01), Vigano′ et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 2006/0040934 (2006-02-01), Cottam et al.
patent: 2226340 (1973-03-01), None
patent: 289262 (1988-11-01), None
patent: 11029475 (1999-02-01), None
patent: 11-106340 (1999-04-01), None
patent: 1110630 (1999-04-01), None
patent: WO-9628148 (1996-09-01), None
patent: WO-9742192 (1997-11-01), None
patent: WO-9809603 (1998-03-01), None
patent: WO-9818490 (1998-05-01), None
patent: WO-9916790 (1999-04-01), None
patent: WO-9941985 (1999-08-01), None
patent: WO-9947643 (1999-09-01), None
patent: WO-0013410 (2000-03-01), None
patent: WO-0044364 (2000-08-01), None
In:Remington's Pharmaceutical Sciences, Eighteenth Edition, Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1122.
The Merck Index, Thirteenth Edition, Budavari, S., et al., (eds.), Merck & Co., Inc., Rahway, N.J., “Etodolac, Entry No. 3905 ”,(1990),p. 685.
Drug Facts and Comparisons, 1995 Edition, Wolters Kluwer Co.,(1995),2775-2789.
Abramson, S. B., et al., “The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs”,Arthritis&Rheumatism, 32 (1), (Jan. 1989),1-9.
Akimoto, Toshihiko , “Abrogation of Bronchial Eosinophilic Inflamation and Airway Hyperreactivity in Signal Transducers and Activators of Transcription (STAT)6-deficient Mice”,Journal of Experimental Medicine, 187(9), (1998),1537-1542.
Alexanian, R. , et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine, 330 (7), (Feb. 17, 1994),484-489.
Andreani, A. , et al., “6-Pyridinylimidazo [2,1-b] thizoles and thizolines as potential cardiotonic agents”,Eur. j. Med. Chem., 20(1), (1986),pp. 93-94.
Andreani, A. , et al., “In-vivo cardiotonic activity of aryl- and pyridyl-substituted fused imidazoles”,Arzneim.-Forsch., 48 (3), (1998),pp. 232-235.
Andreani, A., “Potential antitumor agents, VII, 5-substituted 6- phenylimidazo[2,1-b]thizoles”,Arch. Pharm., 315, (1982),pp. 451-456.
Andreani, A. , et al., “Potential Antitumor Agents. 24. Synthesis and Pharmacological Behaviour of Imidazo[2,1-b]thiazole Guanylhydrazones Bearing at Least One Chlorine”,J.Med.Chem., 39(14), (1996),pp. 2852-2855.
Andreani, A. , et al., “Potential antitumor agents. VIII. Allyl propargyl and cyanomethyl esters of imidazo[2,1-b]thiazole-5-carboxylic acids”,Arch.Pharm., 316(2), (1983),pp. 141-146.
Andreani, A. , et al., “Substituted 6-phenylimidazol[2,1-b]thiazoles and thiazolines as potential cardiotonic agents”,Eur.J.Med.Chem., 19(3), (1984),pp. 219-222.
Andreani, A. , et al., “Synthesis and cardiotonic activity of aryl-or pyridyl-substituted fused imidazoles”,Eur.J.Med.Chem, 29(5), (1994),pp. 339-342.
Andreani, A. , et al., “Synthesis and cardiotonic activity of methylthiophenylimidazo{2,1-b]thiazoles and thiazolines”,Eur.J.Med.Chem., 21(1), (1986),pp. 55-58.
Andreani, A. , et al., “Synthesis of 6-substituted formylimidazo [2,1-b] thiazoles”,Bolletino Chimico Farmaceutico,118 (11), (1979),pp. 694-698.
Andreani, A. , et al., “Synthesis of imidazo[2,1-b]thiazoles as herbicides”,Pharm.Acta Helv., 71(4), (1996),pp. 247-252.
Andreani, A. , et al., “Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH Dehydrogenase”,J.Med.Chem., 38(7), (1995),pp. 1090-1097.
Armianianskii, (1990),245-262.
Barlogie, B , “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.”,Blood, 72(6), (Dec. 1988),2015-2019.
Bataille, R , et al., “Multiple Myeloma”,New England Journal of Medicine, 336, (1997),1657-1664.
Becker-Scharfenkamp, U. , et al., “Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography, 621 (2), (Nov. 24, 1993),pp. 199-207.
Bellosillo, Beatriz , et al., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood, 92 (4), (Aug. 15, 1998),1406-1414.
Berendes, U. , et al., “Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine”,Enantiomer, 1, Abstract Only, Chemical Abstracts, Abstract No. 126:207064q,(1996),415-422.
Brenna, E. , et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron, 53, (1997),17769-17780.
Brocks, D. R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics, 26 (4), (1994),pp. 259-274.
Burnett, J. C., et al., “Atrial Natriutetic Peptide Elevation in Congestive Heart Failure in the Human”,Science, 231, (Mar. 7, 1986),1145-1147.
Burnett, J. C., et al., “Effects of synthetic atrial natriuretic factor on renal function and renin release”,American Journal of Physiology: Renal, Fluid and Electrolyte Physiology, 16(5), (Nov. 1984),pp. F863-F866.
Carson, D. A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2'-arabino-fluoro-2′-deoxyadenosine”,Proceedings of the National Academy of Sciences USA, 89 (7), (Apr. 1, 1992),2970-2974.
Chinetti, G. , et al., “Activation of Proliferator-activated Receptors alpha and Y Induces Apoptosis of Human Monocyte-derived Macrophages”,Journal of Biological Chemistry, 273 (40), (Oct. 2, 1998),25573-25580.
Coppola, Gary M., “Chemisrty of 2H-3, 1-Benzoxazine-2, 4(1H)-dione (Isatoic Anhydride). 2. Reactions with Thiopseudoreas and Carbanions”,Journal of Organic Chemistry, (1976),825-831.
Cordon-Cardo, C. , et al., “Genetic Studies and Molecular Markers of Bladder Cancer”,Seminars in Surgical Oncology, 13 (5), (1997),pp. 319-327.
Cunningham, D , et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology, 12, (1994),764-768.
Dancescu, M , “Interleukin 4 Protects Chronic Lymphocytic Leukemic B Cells from Death by Apoptosis and Upregulates BcI-2 Expression”,J. Exp. Med., (1992),1319-1326.
Demerson, C. A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry, 19 (3), (1976),pp. 391-395.
Demerson, C. A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem., 26 (12), (Dec. 1983),pp. 1778-1780.
Donehower, L. A., et al., “Mice Deficient For p53 Are Developmentally Normal But Susceptible to Spontaneous Tumours”,Nature, 356, (Mar. 19, 1992),pp. 215-221.
Drachenberg, D. E., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology, 18 (1), (J

Affiliated with

Also associated with

Rating

Compounds having activity as inhibitors of apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds having activity as inhibitors of apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having activity as inhibitors of apoptosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4127542